Anti-CD74 IgA antibodies are most sensitive and specific to identify young male axSpA patients, data from @XBaraliakos and others: Abstract FRI0312 #EULAR2020 @RheumNow https://t.co/yrevk8Wsiw https://t.co/kzcje2rRNa

• EULAR Abstract Archive

ASAS modification of the Berlin algorithm and the duet algorithm for diagnosing axSpA : results from the screening in axSpA for psoriasis, iritis, and colitis cohort: Abstract FRI0298 #EULAR2020 @RheumNow https://t.co/BkG7c2riRb https://t.co/f63MsxWmd3

• EULAR Abstract Archive

Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS

• EULAR Abstract Archive

The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis, & Colitis Presenting With Undiagnosed Back Pain: All IBP criteria have poor diagnostic utility for dx of axSpA, esp in PsO Abs SAT0378 #EULAR2020 @RheumNow https://t.co/Y7sbtJtm3U https://t.co/P9q7uJozZ9

• EULAR Abstract Archive

Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7

• EULAR Abstract Archive

Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, VTE risk looks very reassuring #EULAR2020 @RheumNow https://t.co/Ld2tpu7UT5 https://t.co/sZqadeUTh8

• EULAR Abstract Archive

The first randomized clinical trial of convalescent plasma in #COVID19, reported by Li et al in JAMA suggests that high titer antibody against #SARSCoV2 may have antiviral efficacy https://t.co/6YIib2GXGX

• A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Sign…

Great talk on inflammasomes at #EULAR2020 by @dave_boucher: 4th June, 1:15pm, Ansell: Inflammasome activation in rheumatic diseases: mechanisms and perspectives for therapy @RheumNow https://t.co/HTWVxt4FMz

Replacing radiographic sacroiliitis with MRI structural damage doesn't change the classifciation of axSpA signifciantly @RheumNow #EULAR2020 Abstract SAT0384 https://t.co/MTTf4fHjYT

Preliminary definition of a +MRI for struc lesions in the SIJs in axSpA: Erosion in ≥2 consec slices or in ≥3 SIJ quad and fat lesion w depth >1cm in ≥1 SIJ quad are high priority for def an MRI struc lesion of axSpA. Abs OP0079 #EULAR2020 @RheumNow https://t.co/9RlSOUviJQ https://t.co/l4XiQDj8e4

• EULAR Abstract Archive

Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0

• E-CONGRESS

1/2 We all have hopes and dreams, and we all need to support ourselves, our families and our communities reach their full potential. Racism, bigotry and hate have no place in a civilised respectful world.

2/2 We all have a part to play by stepping up and making a difference, sometimes in a small way, sometimes in a bigger, but we are all presented with opportunities to do the right thing. Making that choice and taking that action is showing you care. https://t.co/Zk3VcnJjBw

I'm really humbled by the amazing ongoing effort to collect cases for @rheum_covid. So many ppl are working tirelessly to help including the steering committee, patients & the pt board, contrib. rheums & the CASC. Please continue to contribute cases. Thank you 🙏 https://t.co/cK4FZXquMp

And another one! No association of MTX with worsening of ILD in this study by Men-Vazquez et al. #EULAR2020 https://t.co/X7C6KyC29L